Ratiopharm attracts bids above 2 bln eur -sources - News

Runway Angels
The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.
Smartphone Guide
Here's a need-to-know guide to nine devices, based on features, price, network and platform.
Wines for the Holidays
Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES

A Healthier & Wealthier You
Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.
The Billionaire BFF's
Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?
The Many Myths of Coca-Cola
Can you tell which statements are true, and which ones are just rumors?

SPECIAL REPORTS

Winterizing Your Portfolio
If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.
Investor's Guide to Real Estate
Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.
Alternative Investing
Stocks and bonds? Sure. But it's a big world out there for investors.

CNBC ON DIGG

Ratiopharm attracts bids above 2 bln eur -sources

By: AFX | 05 Nov 2009 | 04:35 AM ET

Text Size

FRANKFURT, Nov 5 (Reuters) - German generic drugmaker Ratiopharm, put up for sale to cut its owner's debt, has attracted several first-round bids above 2 billion euros ($2.95 billion), two people familiar with the procedure told Reuters on Thursday. Some of the bids were significalntly above 2 billion euros, the sources added. (Reporting by Philipp Halstrick, Ludwig Burger and Frank Siebelt) ($1=.6782 Euro) Keywords: RATIOPHARM/SOURCES (ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters Messaging: ludwig.burger.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.

The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

Tools: